Autologous IL-12/Multi-targeted Primed T-cells RPTR 168
autologous il-12/multi-targeted primed t-cells rptr 168
"A preparation of genetically modified, multi-antigen-targeted autologous T-lymphocytes, tethered with the human immunostimulatory cytokine interleukin-12 (IL-12), with potential immunostimulating and antineoplastic activities. RPTR 168 is prepared from monocyte-derived dendritic cells (moDCs) that are pulsed with five tumor-associated antigens (TAAs) to expand cytotoxic T-lymphocytes (CTLs) that are subsequently loaded with IL-12. Upon administration, the autologous IL-12/multi-targeted primed T-cells RPTR 168 specifically target tumor cells expressing the five TAAs, which lead to a specific cytotoxic T-lymphocyte (CTL)-mediated killing of these tumor cells. In addition, IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFN-g), activating natural killer cells (NKs), and inducing CTL responses, which may further increase tumor cell death and decrease tumor cell proliferation."